{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:09:08Z","timestamp":1789654148063,"version":"4.0.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartrhythmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Rhythm"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.hrthm.2026.03.1942","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:29:27Z","timestamp":1774970967000},"page":"e2151-e2161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adenovirus-associated viral vector-based gene-replacement therapy for the treatment of arrhythmogenic cardiomyopathy: A risk\u2013benefit perspective in an evolving field"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3432-070X","authenticated-orcid":false,"given":"Alessio","family":"Gasperetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Calkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Barth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrthm.2026.03.1942_bib1","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/j.hrthm.2019.05.007","article-title":"2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy","volume":"16","author":"Towbin","year":"2019","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib2","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.jacc.2016.02.062","article-title":"Etiology of sudden death in sports: Insights From a United Kingdom Regional Registry","volume":"67","author":"Finocchiaro","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib3","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.hrthm.2020.03.007","article-title":"Novel risk calculator performance in athletes with arrhythmogenic right ventricular cardiomyopathy","volume":"17","author":"Gasperetti","year":"2020","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib4","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.008843","article-title":"Impact of exercise restriction on arrhythmic risk among patients with arrhythmogenic right ventricular cardiomyopathy","volume":"7","author":"Wang","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib5","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib6","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007616","article-title":"Early preventive treatment with enalapril improves cardiac function and delays mortality in mice with arrhythmogenic right ventricular cardiomyopathy Type 5","volume":"14","author":"Dom\u00ednguez","year":"2021","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib7","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.jacc.2023.12.015","article-title":"Phenotypic expression and clinical outcomes in patients with arrhythmogenic cardiomyopathies","volume":"83","author":"Bariani","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijcard.2017.10.076","article-title":"Heart transplantation in arrhythmogenic right ventricular cardiomyopathy \u2014 experience from the Nordic ARVC Registry","volume":"250","author":"Gilljam","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib9","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003819","article-title":"Heart failure is common and under-recognized in patients with arrhythmogenic right ventricular cardiomyopathy\/dysplasia","volume":"10","author":"Gilotra","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib11","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.124.004759","article-title":"Patient perceptions of emerging gene therapies for arrhythmogenic right ventricular cardiomyopathy","volume":"17","author":"Schopp","year":"2024","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib12","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/s41431-024-01660-5","article-title":"Genetic therapies for cardiomyopathy: survey of attitudes of the patient community for the CureHeart project","volume":"32","author":"Ormondroyd","year":"2024","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib13","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.hroo.2024.07.019","article-title":"Healthcare professionals\u2019 perspective on the acceptance of gene therapy","volume":"5","author":"Rekker","year":"2024","journal-title":"Heart Rhythm O2"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41569-020-00499-9","article-title":"Targeted delivery of therapeutic agents to the heart","volume":"18","author":"Sahoo","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib15","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jchf.2023.09.015","article-title":"Applications of gene therapy in cardiomyopathies","volume":"12","author":"Argiro","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib16","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib17","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.omtm.2022.02.011","article-title":"Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations","volume":"25","author":"Mendell","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib19","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib20","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy","volume":"54","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.r1548","article-title":"Duchenne gene therapy halted after three deaths and company u turn","volume":"390","author":"Taylor","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/hum.2022.29198.bfs","article-title":"After patient death, FDA places hold on Pfizer Duchenne muscular dystrophy gene therapy trial","volume":"33","author":"Philippidis","year":"2022","journal-title":"Human Gene Ther"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib23","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S1474-4422(23)00313-7","article-title":"Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial","volume":"22","author":"Shieh","year":"2023","journal-title":"Lancet Neurol"},{"issue":"suppl 12","key":"10.1016\/j.hrthm.2026.03.1942_bib24","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/S0735-1097(25)02006-6","article-title":"Study design and rationale of heroic-PKP2: a PHASE 1\/2 study of the safety and efficacy of LX2020 gene therapy in patients with arrhythmogenic cardiomyopathy due to a PLAKOPHILIN-2 pathogenic variant","volume":"85","author":"Aubert","year":"2025","journal-title":"JACC"},{"issue":"suppl 1","key":"10.1016\/j.hrthm.2026.03.1942_bib25","article-title":"Phase I gene therapy clinical trial design of RP-A601 in adult patients with PKP2-arrhythmogenic cardiomyopathy (PKP2-ACM)","volume":"45","author":"Coggins","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib28","author":"Greenberg"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib29","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","article-title":"Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial","volume":"387","author":"Greenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib30","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cardfail.2009.01.013","article-title":"Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID trial), a first-in-human Phase 1\/2 clinical trial","volume":"15","author":"Jaski","year":"2009","journal-title":"J Card Fail"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib31","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1056\/NEJMoa2412392","article-title":"Phase 1 study of AAV9.LAMP2B gene therapy in Danon disease","volume":"392","author":"Greenberg","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib32","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/cvr\/cvaf200","article-title":"First-in-human study of TN-201, an AAV9 gene replacement therapy in MYBPC3 -associated hypertrophic cardiomyopathy: initial safety, pharmacodynamic, and imaging results from MyPEAK-1","volume":"121","author":"Desai","year":"2025","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib33","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1038\/s41467-025-57481-7","article-title":"AAV9-mediated MYBPC3 gene therapy with optimized expression cassette enhances cardiac function and survival in MYBPC3 cardiomyopathy models","volume":"16","author":"Greer-Short","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib34","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/s44161-023-00370-3","article-title":"Plakophilin 2 gene therapy prevents and rescues arrhythmogenic right ventricular cardiomyopathy in a mouse model harboring patient genetics","volume":"2","author":"Bradford","year":"2023","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s43856-024-00450-w","article-title":"AAV9:PKP2 improves heart function and survival in a Pkp2-deficient mouse model of arrhythmogenic right ventricular cardiomyopathy","volume":"4","author":"Wu","year":"2024","journal-title":"Commun Med (Lond)"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib36","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s44161-023-00378-9","article-title":"Therapeutic efficacy of AAV-mediated restoration of PKP2 in arrhythmogenic cardiomyopathy","volume":"2","author":"Kyriakopoulou","year":"2023","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib37","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.123.004305","article-title":"AAV-mediated delivery of Plakophilin-2a arrests progression of arrhythmogenic right ventricular cardiomyopathy in murine hearts: preclinical evidence supporting gene therapy in humans","volume":"17","author":"van Opbergen","year":"2024","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41536-025-00401-6","article-title":"Preclinical efficacy and safety of AAVrh10-based plakophilin-2 gene therapy (LX2020) as a treatment for arrhythmogenic cardiomyopathy","volume":"10","author":"Zhang","year":"2025","journal-title":"NPJ Regen Med"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib39","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCGENETICS.114.001003","article-title":"Clinical presentation, long-term follow-up, and outcomes of 1001 arrhythmogenic right ventricular dysplasia\/cardiomyopathy patients and family members","volume":"8","author":"Groeneweg","year":"2015","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib40","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1089\/hum.2020.217","article-title":"Re: \u201cmoving forward after two deaths in a gene therapy trial of myotubular myopathy\u201d by Wilson and Flotte","volume":"31","author":"Shieh","year":"2020","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib41","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1089\/hum.2021.29182.bfs","article-title":"Fourth boy dies in clinical trial of Astellas\u2019 AT132","volume":"32","author":"Philippidis","year":"2021","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib42","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib43","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1089\/hum.2022.29216.bfs","article-title":"Novartis confirms deaths of two patients treated with gene therapy Zolgensma","volume":"33","author":"Philippidis","year":"2022","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib44","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3233\/JND-221639","article-title":"Meeting Report: 2022 Muscular Dystrophy Association Summit on \u2018Safety and Challenges in Gene Transfer Therapy.\u2019","volume":"10","author":"Lek","year":"2023","journal-title":"JND"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib45","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ijcard.2017.08.026","article-title":"Quality of life metrics in arrhythmogenic right ventricular cardiomyopathy patients: the impact of age, shock and sex","volume":"248","author":"Rhodes","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib46","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1161\/CIRCGENETICS.111.960898","article-title":"General and disease-specific psychosocial adjustment in patients with arrhythmogenic right ventricular dysplasia\/cardiomyopathy with implantable cardioverter defibrillators: a large cohort study","volume":"5","author":"James","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib47","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.123.004133","article-title":"Characterizing decision-making surrounding exercise in ARVC: analysis of decisional conflict, decisional regret, and shared decision-making","volume":"16","author":"Sweeney","year":"2023","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib48","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1016\/j.hrthm.2025.05.007","article-title":"Adeno-associated virus-mediated PKP2 gene therapy confers robust exercise tolerance in a murine model of arrhythmogenic cardiomyopathy","volume":"22","author":"Cerrone","year":"2025","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib49","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax1744","article-title":"Systemic AAV9.LAMP2B injection reverses metabolic and physiologic multiorgan dysfunction in a murine model of Danon disease","volume":"12","author":"Manso","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib50","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib51","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/s13023-025-03893-z","article-title":"In vivo applications and toxicities of AAV-based gene therapies in rare diseases","volume":"20","author":"Zhao","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib52","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib53","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/14712598.2022.2060737","article-title":"Addressing high dose AAV toxicity \u2013 \u2018one and done\u2019 or \u2018slower and lower\u2019?","volume":"22","author":"Kishimoto","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib54","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jcyt.2021.07.013","article-title":"Adenovirus vector-attributed hepatotoxicity blocks clinical application in gene therapy","volume":"23","author":"Wang","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib55","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV Serotypes 1\u20139 mediated gene expression and tropism in mice after systemic injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib56","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143780","article-title":"Overcoming innate immune barriers that impede AAV gene therapy vectors","volume":"131","author":"Muhuri","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib57","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI79213","article-title":"Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy","volume":"125","author":"Chandler","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib58","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3389","article-title":"Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas","volume":"47","author":"Nault","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib59","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","article-title":"Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B","volume":"28","author":"George","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib60","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: A case series","volume":"231","author":"Chand","year":"2021","journal-title":"J Pediatr"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib61","volume":"70","author":"Sherafat","year":"2021"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib65","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.hrthm.2025.01.038","article-title":"Top stories on advancements in gene therapy for inherited arrhythmogenic diseases: from preclinical studies to initial results in patients","volume":"22","author":"Cerrone","year":"2025","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib66","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.hrthm.2025.10.041","article-title":"Top stories on cardiac gene therapy delivery","volume":"23","author":"Bianan","year":"2026","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.hrthm.2025.03.1513","volume":"22","author":"Paterson","year":"2025","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib68","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/CIRCULATIONAHA.124.070236","article-title":"Novel human heart\u2013derived natural adeno-associated virus capsid combines Cardiospecificity with cardiotropism in vivo","volume":"152","author":"Zeissler","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib69","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/jamacardio.2016.5034","article-title":"Evaluation of structural progression in arrhythmogenic right ventricular dysplasia\/cardiomyopathy","volume":"2","author":"Mast","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib70","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1161\/CIRCULATIONAHA.125.074058","article-title":"Family screening in relatives at risk for Plakophilin-2\u2013Associated arrhythmogenic right ventricular cardiomyopathy","volume":"152","author":"Muller","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib71","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jcmg.2025.03.018","article-title":"Disease progression in exercise-induced arrhythmogenic cardiomyopathy compared with arrhythmogenic right ventricular cardiomyopathy","volume":"18","author":"Aaserud","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib72","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/jamacardio.2021.6016","article-title":"Association of premature ventricular contraction burden on serial Holter monitoring with arrhythmic risk in patients with arrhythmogenic right ventricular cardiomyopathy","volume":"7","author":"Gasperetti","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.hrthm.2026.03.1942_bib73","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.hrthm.2018.01.031","article-title":"Predicting arrhythmic risk in arrhythmogenic right ventricular cardiomyopathy: a systematic review and meta-analysis","volume":"15","author":"Bosman","year":"2018","journal-title":"Heart Rhythm"}],"container-title":["Heart Rhythm"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527126022253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527126022253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T09:05:46Z","timestamp":1787735146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1547527126022253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":69,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1547527126022253"],"URL":"https:\/\/doi.org\/10.1016\/j.hrthm.2026.03.1942","relation":{},"ISSN":["1547-5271"],"issn-type":[{"value":"1547-5271","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adenovirus-associated viral vector-based gene-replacement therapy for the treatment of arrhythmogenic cardiomyopathy: A risk\u2013benefit perspective in an evolving field","name":"articletitle","label":"Article Title"},{"value":"Heart Rhythm","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrthm.2026.03.1942","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Heart Rhythm Society. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}